Antenatal corticosteroids result in substantial decrease in neonatal morbidity and mortality by specifically reducing the risk of respiratory distress syndrome, intraventricular hemorrhage and neonatal death among premature infants. No human randomized study has formally compared betamethasone and dexamethasone, the preferred corticosteroids for antenatal therapy, with regards to their effectiveness in reducing neonatal morbidities and mortality.

Our objective was to compare betamethasone with dexamethasone in terms of effectiveness in reducing perinatal morbidities and mortality among preterm infants.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study

We conducted a double blind placebo-controlled randomized trial of antenatal betamethasone compared to dexamethasone among women at risk of preterm deliveries at Stony Brook University Hospital from August 1, 2002 through July 31, 2004. We excluded women with clinical chorioamnionitis, major fetal structural anomalies, fetal chromosomal abnormalities, prior antenatal steroid exposure, and use of betamethasone or dexamethasone for other medical indications, quadruplets and higher order multiple gestation and those who declined enrollment. Consenting women were randomly allocated to one of two groups by the Pharmacy using computer generated random numbers. The statistical analysis was performed in accordance of the intention-to-treat principle.

Student t test, Chi square and Fisher exact test were used for analysis. A P value of < .05 was considered statistically significant.

Intervention(s) in this Clinical Trial

• Drug: Betamethasone(Celestone soluspan) and Dexamethasone

Primary Measures

• Respiratory distress syndrome
• Intraventricular hemorrhage
• Neonatal mortality

Secondary Measures

• Periventricular leukomalacia
• Necrotizing enterocolitis
• Neonatal sepsis

Inclusion Criteria:

• Women in preterm labor with intact membranes
• Women with preterm premature rupture of membranes
• Women been delivered for fetal and maternal indications
• Gestational age between 24 and 33 6/7 weeks’.

Exclusion Criteria:

• Clinical chorioamnionitis
• known major fetal structural anomalies,
• known fetal chromosomal abnormalities,
• prior antenatal steroid exposure,
• quadruplets and higher order multiple gestation
• Women who declined enrollment.

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 45 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: University of Oklahoma

Overall Clinical Trial Officials and Contacts

Andrew A Elimian, M.D Principal Investigator Stony Brook University  

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00418353

Study ID Number: 20024615

ClinicalTrials.gov Identifier: NCT00418353

Health Authority: United States: Institutional Review Board